Table 2.
Secondary measures (intention to treat analysis; figures are numbers (percentages) unless stated otherwise)
| Hypericum (n=122) | Paroxetine (n=122) | Difference (hypericum minus paroxetine) (95% CI), P value | |
|---|---|---|---|
| Change from baseline to day 42: | |||
| MADRS (mean (SD); median) | 16.4 (10.7); 17.0 | 12.6 (10.6); 14.0 | 3.8 (1.1 to 6.5), 0.01* |
| BDI (mean (SD); median)† | 10.2 (10.3); 9.0 | 7.0 (9.3); 5.5 | 3.2 (0.7 to 5.7), 0.01* |
| Scores by day 42: | |||
| Clinical global impressions: | |||
| Item 1 improved by ≥2 categories | 71 (58) | 52 (43) | 16 (3 to 28), 0.02‡ |
| Item 2 much or very much improved | 83 (68) | 70 (57) | 11 (-1 to 23), 0.09‡ |
| Item 3 marked therapeutic effect | 49 (40) | 36 (30) | 11 (-1 to 23), 0.08‡ |
| Global efficacy self rating very good or good | 65 (53) | 55 (45) | 8 (-4 to 21), 0.20‡ |
MADRS=Montgomery-Åsberg depression rating scale; BDI=Beck depression inventory.
*
t test for difference (calculated for pooled data from both study stages).
†
119 in hypericum group, 120 in paroxetine group.
‡
χ2 test for difference (calculated for pooled data from both study stages).